Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.

Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y; Diabetes Prevention Program Research Group..

Int J Obes (Lond). 2008 Oct;32(10):1537-44. doi: 10.1038/ijo.2008.134. Erratum in: Int J Obes (Lond). 2009 Jan;33(1):182.


The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.

Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH.

Lancet. 2008 May 24;371(9626):1783-9. doi: 10.1016/S0140-6736(08)60766-7.


The prevention of type 2 diabetes.

Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM; Diabetes Prevention Program Research Group..

Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):382-93. doi: 10.1038/ncpendmet0843. Review.


Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.

Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K.

BMJ. 2007 Feb 10;334(7588):299. Review.


Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group..

Lancet. 2006 Nov 11;368(9548):1673-9.


Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators., Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770.


Effect of weight loss with lifestyle intervention on risk of diabetes.

Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J.

Diabetes Care. 2006 Sep;29(9):2102-7.


The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP)..

Diabetologia. 2006 Feb;49(2):289-97.


The burden of mortality attributable to diabetes: realistic estimates for the year 2000.

Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H.

Diabetes Care. 2005 Sep;28(9):2130-5.


Trying to predict the future for people with diabetes: a tough but important task.

Engelgau MM.

Ann Intern Med. 2005 Aug 16;143(4):301-2. No abstract available.


Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

Eddy DM, Schlessinger L, Kahn R.

Ann Intern Med. 2005 Aug 16;143(4):251-64.


Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.

Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E; Diabetes Prevention Program Research Group..

Diabetes. 2005 May;54(5):1566-72.


Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M; Diabetes Prevention Program Research Group..

Diabetes Care. 2005 Apr;28(4):888-94.


The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group..

Ann Intern Med. 2005 Mar 1;142(5):323-32.


Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program.

Diabetes Prevention Program Research Group..

Diabetes Care. 2005 Jan;28(1):138-44.


Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group..

N Engl J Med. 2004 Dec 23;351(26):2683-93.


Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Wild S, Roglic G, Green A, Sicree R, King H.

Diabetes Care. 2004 May;27(5):1047-53.


Follow-up report on the diagnosis of diabetes mellitus.

Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus..

Diabetes Care. 2003 Nov;26(11):3160-7. Review. No abstract available.


Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.

Diabetes Prevention Program Research Group..

Diabetes Care. 2003 Apr;26(4):977-80.


Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group..

Lancet. 2002 Jun 15;359(9323):2072-7.

Items per page

Supplemental Content

Support Center